Pfizer Inc (PFE): Our Calculation of Intrinsic Value

Key Takeaways

• DCF values Pfizer at $14‑15 per share.
• Current market price around $27, implying 45% overvaluation.
• Post‑COVID cash flow normalizes, limiting growth.
• Patent cliffs and pipeline risk pressure future earnings.
• Dividend yield remains attractive despite valuation concerns.

Summary

Our weekly DCF model values Pfizer Inc. at roughly $14‑15 per share, far below its current trading level near $27. The analysis uses a 9% discount rate, 2% terminal growth, and projects free cash flow stabilizing around $10 billion by 2029, yielding an enterprise value of $133.7 billion and equity value of $83.3 billion. After the pandemic surge, Pfizer is reverting to a traditional large‑cap pharma profile, facing slower growth and patent‑cliff pressures. The resulting margin of safety is approximately –45%, indicating modest overvaluation.

Pulse Analysis

Pfizer’s valuation story illustrates how a post‑pandemic revenue correction can reshape a mega‑cap pharma’s investment thesis. The discounted cash flow model applied a 9% weighted average cost of capital and modest 2% perpetual growth, reflecting a realistic view of cash‑flow generation once the COVID‑19 vaccine and antiviral windfalls fade. By anchoring free cash flow forecasts at $9‑10 billion through 2029, the model arrives at an enterprise value of $133.7 billion and an intrinsic share price near $14‑15, a stark contrast to the roughly $27 market level.

The divergence stems from several structural headwinds. Patent expirations on blockbuster drugs erode revenue streams, while the company’s ambitious acquisition strategy in oncology and specialty therapeutics introduces integration risk. Moreover, pipeline execution remains uncertain; investors are awaiting data from late‑stage trials that could revive growth momentum. Despite these challenges, Pfizer’s scale, robust R&D infrastructure, and a dividend yield above 4% provide a defensive cushion, especially for income‑focused portfolios.

For market participants, the key question is whether the valuation gap will narrow as new products reach commercialization or if the overvaluation persists, exposing shareholders to downside risk. A successful launch in oncology or immunology could compress the discount, while continued earnings volatility may keep the stock under pressure. Consequently, prudent investors should monitor trial outcomes, patent cliff timelines, and cash‑flow trends, balancing the attractive dividend against the potential for further price correction.